Evidence mapPaperPMID 41737389Full record

ReviewFrontiers in medicine2026

Prostaglandin E

Dario Rusciano, Caterina Gagliano, Alessandro Avitabile, José Fernando Maya-Vetencourt

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dario RuscianoNeurovisual Science Technology (NEST), Catania, Italy.
Caterina GaglianoFaculty of Medicine and Surgery, University of Enna "Kore", Enna, Italy.
Alessandro AvitabileNeurovisual Science Technology (NEST), Catania, Italy.
José Fernando Maya-VetencourtDepartment of Biology, Physiology Institute, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic retinal diseases, including retinal vein and artery occlusions, diabetic retinopathy, and non-arteritic ischemic optic neuropathy, are major causes of vision loss worldwide and remain incompletely addressed by current therapies. Prostaglandin E1 (PGE

Indexed as

anti-inflammatory activityanti-thrombotic and rheological effectsdiabetic retinopathyendothelial protectionneuroprotective and mitochondrial benefitsnon-arteritic ischemic optic neuropathyretinal vein and artery occlusionsvasodilation

Identifiers

PMID41737389
PMCPMC12926496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.